Floatz logo

Therapeutic Asset Ratings

178 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
PROPRANOLOL
Ureter Transitional Cell Carcinoma
Emory UniversityP2CCC (53)
PROPRANOLOL
Urethra Transitional Cell Carcinoma
Emory UniversityP2CCC (53)
PROPRANOLOL
Urothelial Carcinoma
Emory UniversityP2CCC (53)
PROPRANOLOL
Triple-Negative Breast Carcinoma
Emory UniversityP2CCC (53)
PROPRANOLOL
Urinary Bladder Cancer
Emory UniversityP2CCC (53)
PROPRANOLOL
Malignant Renal Pelvis Neoplasm
Emory UniversityP2CCC (53)
PROPRANOLOL
Ureter Cancer
Emory UniversityP2CCC (53)
PROPRANOLOL
Urethra Cancer
Emory UniversityP2CCC (53)
Recombinant Human Hyaluronidase
Cutaneous Melanoma
Emory UniversityP2CCC (53)
Recombinant Human Hyaluronidase
Melanoma
Emory UniversityP2CCC (53)
Toripalimab
Colon Carcinoma
Emory UniversityP2CCC (53)
Triiodothyronine
Glioblastoma
Emory UniversityP2CCC (53)
Venetoclax
CCND1 Positive
Emory UniversityP2CCC (53)
Zanidatamab
Colon Carcinoma
Emory UniversityP2CCC (53)
Zanidatamab
Rectal Cancer
Emory UniversityP2CCC (53)
Zanidatamab
Rectal Carcinoma
Emory UniversityP2CCC (53)
Zanidatamab
Malignant Colon Neoplasm
Emory UniversityP2CCC (53)
Zofran
CCND1 Positive
Emory UniversityP2CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Melanoma
Emory UniversityP2CCC (52)
Defactinib
Lung Cancer
Emory UniversityP2CCC (51)
FUROSEMIDE
Prostate Adenocarcinoma
Emory UniversityP2CCC (51)
Zanidatamab
Colorectal Carcinoma
Emory UniversityP2CCC (51)
FMISO
Hepatocellular Carcinoma
Emory UniversityP2CCC (49)
ABATACEPT RECOMBINANT
Major Depressive Disorder
Emory UniversityP2CCC (48)
Avelumab
Malignant Renal Pelvis Neoplasm
Emory UniversityP2CCC (48)
Showing 101 to 125 of 178 assets
PreviousPage 5 of 8Next